Icon Plc $ICLR Shares Sold by Sei Investments Co.

Sei Investments Co. decreased its stake in shares of Icon Plc (NASDAQ:ICLR) by 3.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 757,489 shares of the medical research company’s stock after selling 28,448 shares during the quarter. Sei Investments Co.’s holdings in Icon were worth $83,824,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. State of Wyoming boosted its stake in shares of Icon by 41.3% in the 1st quarter. State of Wyoming now owns 3,082 shares of the medical research company’s stock valued at $341,000 after buying an additional 901 shares during the period. Cetera Investment Advisers increased its stake in shares of Icon by 17.6% during the first quarter. Cetera Investment Advisers now owns 14,859 shares of the medical research company’s stock worth $1,644,000 after buying an additional 2,221 shares during the period. Militia Capital Management LLC purchased a new stake in shares of Icon during the first quarter worth approximately $2,523,000. NewEdge Wealth LLC raised its holdings in Icon by 81.9% in the first quarter. NewEdge Wealth LLC now owns 8,038 shares of the medical research company’s stock valued at $889,000 after acquiring an additional 3,619 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in Icon by 17.0% in the first quarter. First Trust Advisors LP now owns 2,760 shares of the medical research company’s stock worth $305,000 after acquiring an additional 401 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on ICLR. Barclays boosted their price target on shares of Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $165.00 price objective on shares of Icon in a research report on Friday, May 29th. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $126.00 to $185.00 in a research note on Thursday, June 25th. Truist Financial raised Icon from a “hold” rating to a “buy” rating and increased their target price for the company from $159.00 to $207.00 in a report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. increased their target price on Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $168.73.

Icon Trading Down 2.7%

NASDAQ ICLR opened at $165.76 on Friday. The firm’s fifty day moving average price is $151.11 and its 200 day moving average price is $136.43. Icon Plc has a 12 month low of $66.57 and a 12 month high of $203.91. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 1.14. The company has a market capitalization of $12.69 billion, a price-to-earnings ratio of 29.49, a price-to-earnings-growth ratio of 8.36 and a beta of 1.22.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.